Immunotherapy plus chemotherapy shows promise against tough nasopharyngeal cancer
NCT ID NCT05201859
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This phase 2 trial tests whether adding the immunotherapy drug sintilimab to the chemotherapy drug capecitabine can better prevent nasopharyngeal cancer from returning after initial treatment. About 150 patients whose cancer did not fully respond to induction chemotherapy will receive either the combination or capecitabine alone. The study tracks how long patients stay cancer-free and monitors side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- sintilimab (an immunotherapy drug) and capecitabine (a chemotherapy drug)
- What this could lead to
- If successful, this combination could improve the chance of keeping nasopharyngeal cancer from coming back after standard treatment.
- What could go wrong
- This is a mid-stage trial with only 150 participants, so results may not apply to everyone. Immunotherapy can cause immune-related side effects, and the added benefit over capecitabine alone is not yet proven.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NASOPHARYNGEAL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, 510060, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could adding extra chemo before standard therapy beat nasopharyngeal cancer?
- Smart T-Cell engager aims to outsmart tumors in first human test
- Immunotherapy combo shows promise in shrinking Hard-to-Treat head and neck tumors
- Immunotherapy duo aims to shrink nasopharyngeal tumors before standard treatment
- New radiation approach aims to reduce dry mouth in throat cancer patients
- New pill-chemo combo takes on hard-to-treat cancers